Tempus AI, Inc. (TEM) Debt to Equity Ratio: 1.66
Is Tempus AI, Inc.’s debt to equity ratio high or low?
Tempus AI, Inc.'s debt to equity ratio of 1.66 is 67% below its 1-year average of 4.99, near the low end of its 1-year range (1.66–8.31).
As of Friday, June 12, 2026. 66.70% below its 12-month average of 4.99.
TEM Debt to Equity Ratio Chart
TEM Average Debt to Equity Ratio Chart
TEM Current vs Average Debt to Equity Ratio Chart
TEM Debt to Equity Ratio Metrics
DEBT TO EQUITY RATIO
1.66
DEBT TO EQUITY RATIO AVG TTM
4.99
DEBT TO EQUITY RATIO AVG 3Y
4.99
DEBT TO EQUITY RATIO AVG 5Y
4.99
DEBT TO EQUITY RATIO AVG 10Y
4.99
DEBT TO EQUITY RATIO AVG 15Y
4.99
DEBT TO EQUITY RATIO AVG 20Y
4.99
CURRENT VS TTM AVG
-66.70%
CURRENT VS 3Y AVG
-66.70%
CURRENT VS 5Y AVG
-66.70%
CURRENT VS 10Y AVG
-66.70%
CURRENT VS 15Y AVG
-66.70%
CURRENT VS 20Y AVG
-66.70%
TEM Competitors' Debt to Equity Ratio
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempus AI, Inc. (TEM) | $8.65B | 1.66 | 4.99 | 4.99 | 4.99 |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | 0.97 | 0.88 | 0.91 | 0.99 |
| Bio-Rad Laboratories, Inc. (BIO) | $7.91B | 0.21 | 0.21 | 0.18 | 0.13 |
| Baxter International Inc. (BAX) | $10.58B | 1.63 | 1.78 | 2.05 | 1.83 |
| Hims & Hers Health, Inc. (HIMS) | $6.44B | 2.34 | 1.18 | 0.60 | 0.40 |
| Align Technology, Inc. (ALGN) | $12.64B | 0.03 | 0.03 | 0.03 | 0.03 |
| Solventum Corporation (SOLV) | $13.72B | 1.00 | 1.85 | 1.10 | 0.74 |
| Hologic, Inc. (HOLX) | $16.97B | 0.52 | 0.52 | 0.55 | 0.69 |
| 23andMe Holding Co. (ME) | $15.31M | -2.56 | 0.27 | 0.25 | 0.34 |
| Moderna, Inc. (MRNA) | $19.70B | 0.22 | 0.15 | 0.11 | 0.10 |
Financial Health
Debt/Equity
1.66
Current Ratio
3.13
Tempus AI, Inc. Debt to Equity Ratio Formula & Definition
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Tempus AI, Inc. Debt to Equity Ratio FAQ
- What is the debt to equity ratio for Tempus AI, Inc. (TEM)?
- The debt to equity ratio for TEM stock is 1.66.
- Is Tempus AI, Inc.'s debt to equity ratio high or low?
- Tempus AI, Inc.'s debt to equity ratio of 1.66 is 67% below its 1-year average of 4.99, near the low end of its 1-year range (1.66–8.31).
- What is the TTM average debt to equity ratio for Tempus AI, Inc. (TEM)?
- The TTM average debt to equity ratio for TEM stock is 4.99.
- What is the 3Y average debt to equity ratio for Tempus AI, Inc. (TEM)?
- The 3Y average debt to equity ratio for TEM stock is 4.99.
- What is the 5Y average debt to equity ratio for Tempus AI, Inc. (TEM)?
- The 5Y average debt to equity ratio for TEM stock is 4.99.
- What is the 10Y average debt to equity ratio for Tempus AI, Inc. (TEM)?
- The 10Y average debt to equity ratio for TEM stock is 4.99.
- What is the 15Y average debt to equity ratio for Tempus AI, Inc. (TEM)?
- The 15Y average debt to equity ratio for TEM stock is 4.99.
- What is the 20Y average debt to equity ratio for Tempus AI, Inc. (TEM)?
- The 20Y average debt to equity ratio for TEM stock is 4.99.
Tempus AI, Inc. Debt to Equity Ratio History
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2025-12-31 | 1.66 |
| 2024-12-31 | 8.31 |
Related Metrics
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky